Skip to main content
Clinical Trials/NCT02022579
NCT02022579
Unknown
Not Applicable

A Multi-Center Study Evaluating the Utility of Diffusion Weighted Imaging for Detection and Diagnosis of Breast Cancer

American College of Radiology Imaging Network1 site in 1 country100 target enrollmentJanuary 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
BIRADS 3
Sponsor
American College of Radiology Imaging Network
Enrollment
100
Locations
1
Primary Endpoint
Apparent Diffusion Coefficient (ADC)
Last Updated
7 years ago

Overview

Brief Summary

A type of magnetic resonance imaging called diffusion weighted imaging (DWI) will be tested to define cancerous from non-cancerous lesions in the breast.

Detailed Description

For this study, the investigators plan to evaluate DWI scans performed in women with breast lesions identified by conventional breast MRI. The investigators will determine whether an ADC threshold can be defined for distinguishing benign and malignant lesions on DWI, assess the difference in ADC cutoffs for mass and non-mass lesions, and investigate the potential improvement in accuracy using techniques such as nonzero minimum b-value (to remove perfusion effects in the ADC measures) and normalized ADC measures (to account for variations in water content and other factors).

Registry
clinicaltrials.gov
Start Date
January 2014
End Date
March 2019
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Willing and able to provide written informed consent;
  • 18 years of age or older;
  • Successful completion of breast MR examination with DWI required by protocol;
  • Undiagnosed breast lesion (BI-RADS 3, 4, or 5) identified on MRI. The BI-RADS assessment must refer to a focal finding within the breast (i.e. mass, non-mass, or focus) as opposed to diffuse processes (e.g. background parenchymal enhancement, skin thickening) or lesions outside the subcutaneous breast (e.g. axillary lymph nodes, focal skin lesions, osseous lesions, etc.).

Exclusion Criteria

  • Participants with current or recent history (within 6 months prior to the MRI) of chemotherapy for cancer;
  • Neoadjuvant chemotherapy between MRI and confirmation of lesion outcome (study lesions must be biopsied prior to undergoing any chemotherapy);
  • Pregnant (if a female is of childbearing potential - defined as a pre-menopausal female capable of becoming pregnant - confirmation of pregnancy status per the site's standard of practice should be done prior to MRI);
  • Unwilling or not suitable to undergo MRI or use the contrast agent gadolinium.

Outcomes

Primary Outcomes

Apparent Diffusion Coefficient (ADC)

Time Frame: 1 year

Whether the Apparent Diffusion Coefficient (ADC), when used systematically in conjunction with conventional Dynamic Contrast Enhanced-Magnetic Resonance Imaging (DCE-MRI), can reduce the biopsy rate by at least 20% while maintaining sensitivity.

Secondary Outcomes

  • Local and Central Review Comparison (ADC Value Differences)(1 year)
  • Minimum B-Value for Differentiating Lesions(1 year)
  • Combination Variables (ADC Nonzero Minimum B-Value and/or Normalized ADC)(1 year)
  • Optimal ADC Cutoffs by Lesion Type(1 year)
  • ADC Measurements/Ratios to Define Subject Lesion Variations(1 year)

Study Sites (1)

Loading locations...

Similar Trials